SAN DIEGO, CA, August 15, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that a profile of the company and its pipeline of oncology therapies is featured in the most recent issue of BioWorld, one of the most widely read publications in the pharma and biotech industries. The article can be purchased at www.bioworld.com.
The publication noted that: “The San Diego-based biotech has yet to celebrate its first anniversary, but its lead electro immunotherapy candidate, DNA IL-12, is heading into three Phase II trials for melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma (CTCL). The company attributes its enviable maturity to its March spin-out from Inovio Pharmaceuticals Inc., of Blue Bell, Pa. The move allowed Inovio to focus on DNA vaccines, while giving OncoSec the opportunity to develop electrochemical and cytokine-based immune therapies for treating solid tumors via electroporation delivery.”
A previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions The link below provides further information on this trial:(http://www.oncosec.com/news/oncosec-electroimmunotherapy-shows-systemic-effects-of-metastatic-melanoma-tumor-in-more-than-50-percent-of-patients).
OncoSec’s President and CEO, Punit Dhillon said, “We are pleased to receive recognition from a global biotech publication for OncoSec’s lead pipeline immunotherapeutic product. We look forward to reporting additional progress from our Phase II skin cancer trials in Q4.”
BioWorld® Today, the news source of record for the biotechnology industry, is read by biotechnology professionals worldwide for its hard-hitting, objective news reporting. BioWorld Today is delivered via e-mail every business morning, and is also found exclusively online at www.bioworld.com. The BioWorld online web site has been internationally recognized as the most comprehensive resource for strategic biotechnology news and information available today.
OncoSec Medical (OTCBB: ONCS) develops novel ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.